RxDoctor Payments Data

Kathy McKenzie, NP

Family · Bolton, NCNPI 1356967368

Payments from drug & device makers

$3,855in general payments, 2019–2025

Across 124 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$674
  • Bayer$612
  • Novo Nordisk$581
  • Lilly USA, LLC$277
  • AbbVie$197
  • plus $285 from 7 others

What the payments were for

  • Food & beverage$3,855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,855 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,593
Medicare patients
33
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$37,011
FarxigaDapagliflozin Propanediol41$36,921
TrulicityDulaglutide14$26,276
EliquisApixaban25$19,176
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$18,802
LinzessLinaclotide28$17,182
XareltoRivaroxaban18$16,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,940
Repatha SureclickEvolocumab14$7,874
Lagevrio (Eua)Molnupiravir15$4,848
Albuterol Sulfate HfaAlbuterol Sulfate68$2,381
Roflumilast21$1,673
Omeprazole86$1,199
Atorvastatin Calcium175$1,011
Diltiazem 24hr ErDiltiazem Hcl28$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,230$55,72360 claims
Boehringer IngelheimJardiance$21$37,01129 claims
Lilly USA, LLCTrulicity$277$26,27614 claims
AbbVieLinzess$197$17,18228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Bolton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →